CA
NZ
UK
AU
IND
US
Syndax fell 14.02% pre-market after saying its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis, which ends its plans to advance the drug in IPF. The company said the result does not affect ongoing trials of the …
Savara's lead drug MOLBREEVI, an inhaled form of GM-CSF, treats autoimmune pulmonary alveolar proteinosis, a rare lung disease, and its BLA decision is now due on November 22, 2026 after a three-month extension announced in April. The company announced presentations at the CHEST 2026 …
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. Wave Life Sciences reported second-quarter 2026 results on July 30, with revenue of USD 2.3 million versus USD 8.7 million …
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. Aclaris reported second-quarter 2026 results on August 6, with a net loss of USD 21.5 million versus USD 15.4 million …
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. Apimeds Pharmaceuticals US is a clinical-stage company developing Apitox, a bee venom-based toxin given intradermally, which has been used in …
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. InMode reported second-quarter 2026 results on August 5, with revenue of USD 95.6 million, consistent with a year earlier, GAAP …
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. Jaguar Health received USD 16 million of non-dilutive cash in January 2026 under a royalty-free US license of Mytesi and …
SBC Medical Group Holdings Incorporated (NASDAQ:SBC) has a market value near $557 million. The company has been attending investor conferences this month, and the focus is on results and strategy, including expansion into non-aesthetic healthcare and overseas markets.
Scienture Holdings, Inc. (NASDAQ:SCNX), a pharmaceutical company focused on central nervous system and cardiovascular products, is in focus with a market capitalisation near $6.2 million. The company recently launched a product, announced a 1-for-25 reverse split and had trading halted around October 3 with …
Serina Therapeutics, Inc. (NYSE American:SER) is a clinical-stage biotechnology company developing treatments using its POZ polymer platform, with SER-252 (POZ-apomorphine) for advanced Parkinson's disease as its lead program. Its second-quarter 2026 update showed a materially larger cash balance than at the end of 2025, …
Please wait processing your request...